METAVAS MR 35 mg contains Trimetazidine Hydrochloride Modified Release 35 mg. It is an anti-anginal medicine used to improve the energy metabolism of heart cells, helping the heart function more efficiently during reduced blood flow.
Uses:
Long-term treatment of stable angina pectoris (chest pain due to coronary artery disease)
Helps reduce the frequency of angina attacks
Improves exercise tolerance in patients with chronic stable angina
Used as an add-on therapy when first-line anti-anginal medicines are insufficient or not tolerated
Dose:
Adults: Usually 35 mg twice daily with meals, or as directed by a physician
Swallow the modified-release tablet whole; do not crush or chew
Dose adjustment may be required in elderly patients or those with kidney impairment
Do not use for the immediate relief of an acute angina attack
Do not stop or change the dose without medical advice